Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) Short Interest Update

Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) was the recipient of a large increase in short interest in January. As of January 30th, there was short interest totaling 5,022 shares, an increase of 7,746.9% from the January 15th total of 64 shares. Based on an average daily trading volume, of 209,694 shares, the short-interest ratio is currently 0.0 days. Approximately 0.0% of the shares of the company are sold short. Approximately 0.0% of the shares of the company are sold short. Based on an average daily trading volume, of 209,694 shares, the short-interest ratio is currently 0.0 days.

Enzon Pharmaceuticals Trading Down 4.4%

OTCMKTS ENZN traded down $0.00 on Tuesday, reaching $0.06. 208 shares of the stock were exchanged, compared to its average volume of 81,686. Enzon Pharmaceuticals has a one year low of $0.03 and a one year high of $0.17. The firm has a market capitalization of $4.79 million, a PE ratio of -1.29 and a beta of 0.19. The company’s 50-day simple moving average is $0.05 and its two-hundred day simple moving average is $0.06.

Enzon Pharmaceuticals (OTCMKTS:ENZN) last announced its quarterly earnings data on Wednesday, November 12th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter.

About Enzon Pharmaceuticals

Enzon Pharmaceuticals, Inc, headquartered in Piscataway, New Jersey, is a specialized biopharmaceutical company best known for pioneering polyethylene glycol (PEG) technology to enhance the pharmacokinetic properties of therapeutic proteins. Founded in 1981, Enzon has leveraged its PEGylation platform to develop an array of oncology and hematology products with improved half-life and reduced immunogenicity.

The company’s flagship product, Oncaspar (pegaspargase), was originally approved for the treatment of acute lymphoblastic leukemia in pediatric and adult patients, highlighting Enzon’s commitment to oncology.